DXRX – Diaceutics Plc

Diaceutics (LSE:DXRX) used a late-July trading update to put the spotlight squarely on the number it most wants shareholders to follow. In a statement to the market on 29 July 2026, the Belfast-based precision-medicine data specialist said annual recurring revenue (ARR) had climbed 75% year on year to £28.8 million by the half-year point, a step-change that management argues gives it far greater visibility over both future revenue and profit.

For a business that has spent several years coaxing the world's largest drugmakers into buying its diagnostic data on subscription rather than one-off project terms, the change in the shape of revenue matters as much as the headline growth. Recurring income smooths the peaks and troughs of project work, and a rapidly expanding ARR base is precisely the signal that long-term holders of the shares have been waiting for.

What Diaceutics does

Founded in 2005 and listed on London's AIM since 2019, Diaceutics (LSE:DXRX) provides data, analytics and advisory services to the pharmaceutical and biotech industry. Its core asset is DXRX – The Diagnostics Network, a proprietary platform that combines real-world testing data, analytics and scientific advisory work to help drug companies commercialise precision therapies.

The practical problem it addresses is a stubborn one: many patients who could benefit from a targeted therapy are never correctly tested or diagnosed, so the treatment never reaches them. Diaceutics sells the data and insight that help pharma clients close those testing gaps. The company reports that it now works with 18 of the top 20 global pharma companies, and it is led by chief executive Ryan Keeling, who succeeded founder Peter Keeling after a planned transition.

Behind the ARR surge

The trading update covered the six months to 30 June 2026. Alongside the ARR figure, the company reported revenue of £17.5 million, up 20% on the £14.6 million booked a year earlier, and 22% higher on a constant-currency basis. The gap between reported and constant-currency growth is a reminder that a stronger pound has been a modest headwind.

The most striking operating metric sat beneath the top line. Net revenue retention reached 146%, meaning existing customers were, on average, spending almost half as much again as they did a year earlier. That is the mechanism driving the ARR jump: rather than winning a flood of new logos, Diaceutics is deepening and lengthening its relationships with clients it already has, converting them onto multi-year recurring arrangements.

The headline numbers

On the reported figures, H1 2026 revenue of £17.5 million was accompanied by adjusted EBITDA of around £1.1 million, with a gross margin of roughly 87%. The company finished the half debt-free with cash of £8.1 million.

Forward cover looked solid. The total order book stood at £43.7 million, of which £15.7 million was already contracted for the second half. Management said that gave it about 91% visibility over its 2026 revenue expectations. On the customer side, Diaceutics reported 54 customers spanning 99 therapeutic brands, a broader footprint than a year earlier.

How this compares

The half-year update builds on a full-year 2025 that already marked a turn in the company's financial trajectory. For the year to 31 December 2025, Diaceutics reported revenue of £38.4 million, up 20% (24% at constant currency) from £32.2 million, and a return to profitability with pre-tax profit of £0.3 million against a £1.9 million loss the year before. Adjusted EBITDA rose 80% to £7.6 million, lifting the margin to 20% from 13%.

Against that backdrop, the ARR path is instructive. ARR stood at £20.0 million at the end of 2025, itself 19% higher than a year earlier, so the £28.8 million reported at June 2026 represents a marked acceleration in the first half. Perhaps more telling, net revenue retention has jumped from 105% for the 2025 financial year to 146% at the half-year, suggesting the land-and-expand model is gaining traction rather than simply holding steady.

Strategy and growth drivers

Two strands underpin management's plan. The PMx strategy is aimed at turning transactional relationships into enterprise-wide, multi-year recurring contracts, which is what feeds the ARR and retention numbers. The broader Precision for All initiative describes the company's attempt to widen its addressable market beyond its established precision-oncology base.

On our reading, the investment case now rests heavily on whether Diaceutics can keep converting one-off engagements into subscriptions without a corresponding rise in customer churn or discounting. The retention figure suggests early success, but a single reporting period does not establish a trend, and management has been careful to frame the order book, rather than a specific revenue target, as the anchor for its guidance.

Industry and competitive context

The tailwind behind the business is real. Precision medicine and companion diagnostics continue to expand as more therapies are approved with a testing requirement attached, and pharma companies increasingly recognise that poor real-world testing rates erode the commercial return on those drugs.

Diaceutics occupies a relatively specialised niche, but it is not without competition. Contract research organisations, laboratory networks, healthcare data vendors and pharma clients' own in-house analytics teams all offer overlapping capabilities. The company's defence is the breadth of its diagnostic data set and its embedded relationships with the largest drugmakers, both of which are difficult to replicate quickly.

Key risks and uncertainties

Several caveats temper the growth story. Diaceutics remains dependent on the budgets and testing programmes of a small number of very large pharma customers, so concentration risk is meaningful; the loss or slowdown of a major client would be felt disproportionately.

The business is also weighted towards second-half delivery, which places a premium on converting the contracted order book on schedule. Cash of £8.1 million, while adequate for a debt-free company, is lower than it was two years ago, and the constant-currency adjustments show that reported figures remain exposed to sterling's movements against the dollar. Investors should also note that ARR and net revenue retention are management-defined metrics; their trajectory is encouraging, but they are not a substitute for audited profit and cash generation.

Milestones to watch

The immediate items on the calendar are the company's full interim report, which typically follows the summer trading update with detailed profit and cash figures, and progress on converting the £15.7 million of second-half contracted revenue. Beyond that, the full-year 2026 results will show whether the 146% net revenue retention seen at the half-year holds up across a complete cycle.

Fresh enterprise contract wins under the PMx banner, and any commentary on the pace of the Precision for All expansion, will also help gauge whether the first-half momentum is sustainable.

A balanced view

Taken together, the update reinforces a picture of a company moving from lumpy project income towards a more predictable, subscription-led model, with the ARR and retention figures doing the heavy lifting in that narrative. The return to full-year profitability in 2025 and the strong order-book visibility for 2026 lend the story credibility.

At the same time, the shares carry the usual small-cap caveats: customer concentration, second-half execution risk and a cash position that leaves limited room for error. On our reading, the direction of travel is clearly positive, but the durability of the recurring-revenue surge is the variable that will ultimately determine whether the current momentum endures. This article is for information only and does not constitute investment advice.